Zynex has completed the clinical verification trial of its pulse oximeter, NiCO, marking a significant milestone towards the ...
HC Wainwright reissued their buy rating on shares of Zynex (NASDAQ:ZYXI – Free Report) in a report issued on Friday morning,Benzinga reports. The brokerage currently has a $17.00 target price on the ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zynex (ZYXI – Research Report) and KalVista ...
On Thursday, H.C. Wainwright maintained a positive stance on shares of Zynex Inc. (NASDAQ:ZYXI), reiterating a Buy rating and a $17.00 price target for the company's stock, representing ...
Zynex, Inc. ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, ...
On Thursday, H.C. Wainwright maintained a positive stance on shares of Zynex Inc. (NASDAQ:ZYXI), reiterating a Buy rating and a $17.00 price target for the company's stock, representing significant ...
Zynex Inc. ZYXI recently announced the completion of the clinical verification trial of its NiCO pulse oximeter, which was ...
Zynex Inc (NASDAQ:ZYXI) announced that it has completed the clinical verification trial for its NiCO pulse oximeter, a key milestone required to get market clearance for the device from the US ...